Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Volatility indices capture market swings while price indices reflect level movements. This overview shows how the two guide risk-aware investing.
24,433 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
As rates push beyond 6.6%, loan officers saving deals deploy new tactics to preserve contracts, including seller cred...
Retail investors push Ford into meme-stock territory as Wall Street holds, sparking a heated debate about the automak...
POET Technologies has logged a 220% surge over the past year, but traders are contending with signs of a potential co...
A major broker signals a shift toward prediction markets tied to the S&P 500, with Cboe as a partner. This move could...
Bitcoin rose above $60,000, yet a large inflow of BTC to exchanges suggests the rebound could face renewed selling pr...
Bold claims about doubling your money tempt investors. This guide explains realistic paths to potential outsized gain...
Investors often react to headlines about Coinbase and Circle with a knee-jerk fear or optimism. This piece explains w...
A new stake lift from Bright Valley Capital highlights a high-stakes bet on Vipshop’s rebound. We break down what it ...
As Palantir rolls out its Agentic AI Platform, analysts clash over value. This article breaks down the upside, the ri...
The ethereum trust (etha) lost roughly half its value in 2026 while a strong payroll print reinforced a risk-off mood...
A Parabilis Medicines director recently disclosed a substantial stake just after the company’s fresh IPO. This articl...